Kornimate/medical-research-clean huggingface dataset:
extracorporeal photopheresis (ecp) with methoxsalen for chronic graft versus host disease (cgvhd)

Conditions: Chronic Graft Versus Host Disease

Summary: chronic graft-versus-host disease (cgvhd) is a long-lasting complication that can occur after transplants. the transplanted cells seem to fight with the patient's own cells. extracorporeal photopheresis (ecp) is a fairly new procedure for cgvhd. the participant gets a port to hook up to a machine. the machine removes the white blood cells, mixes them with a light-sensitive drug, shines light on it, and puts all the blood back in. this study will find out if patients respond better if they get ecp with methoxsalen, in addition to the pills normally used to treat cgvhd.

the investigation of extracorporeal photopheresis (ecp) plus standard of care (soc) (soc+ecp) in chronic graft-versus-host disease (cgvhd) within prospective, randomized clinical studies is limited, despite its frequent clinical use. this phase 1/pilot study was the first randomized, prospective study to investigate ecp use as first-line therapy in cgvhd, based on the 2015 national institutes of health (nih) consensus criteria for diagnosis and response assessment. adult patients with new-onset (≤3 years of hematopoietic stem cell transplantation) moderate or severe cgvhd were randomized 1:1 to 26 weeks of soc+ecp vs soc (corticosteroids and cyclosporine a/tacrolimus) between 2011 and 2015. the primary endpoint was overall response rate (orr), defined as complete or partial response, at week 28 in the intention-to-treat population (itt).

Eligibility criteria:
inclusion criteria: to be eligible for inclusion in this trial, the patient must have moderate to severe chronic graft-versus-host disease \[defined by the national institutes of health (nih) 2015 consensus criteria\] that started within 3 years after hematopoietic stem cell transplantation (hsct). exclusion criteria: * is intolerant to corticosteroids or hypersensitive to methoxsalen * received certain treatments during time periods disallowed by protocol * has infections and/or requires treatment that (per protocol or in the opinion of the investigator) might compromise: 1. safety and well-being of participant or offspring 2. safety of study staff 3. analysis of results

Keywords: extracorporeal photopheresis therapy methoxsalen cgvhd hematopoietic stem cell transplantation
effects of rhythmic auditory stimulation on movements in individuals at risk for psychotic onset and schizophrenia patients

Conditions: Schizophrenia; Psychosis; Parkinsonism; Dyskinesias

Summary: the purpose of this research is to examine effects of movement training with the aid of rhythmic auditory stimulation (ras) on reducing severity of dyskinesia and bradykinesia in at-risk individuals and schizophrenia patients. the investigators hypothesize that training with the aid of ras reduced severity of bradykinesia and dyskinesia in at-risk individuals as well as in schizophrenia patients.


Eligibility criteria:
for at-risk individuals: the inclusion criteria for at-risk individuals are: 1. a score of or above 9 in the chinese version of the 16-item prodromal questionnaire (cpq-16), or a score of or above 8.18 in the chinese version of community assessment of psychic experiences with 15 items (cape-c15), or a score of or above 17 in schizotypal personality questionnaire-brief (spq-b); 2. a score of or above 22 in the hong kong version of montreal cognitive assessment (hk-moca) to ensure that they can understand instructions; 3. a score of or above 60 in the chinese version of edinburgh handedness inventory to ensure that they are right-handed. 4. the age ≥ 13 years. the inclusion criteria for healthy controls are: 1. a score below the cut-off score of cpq-16, cape-c15, and spq-b; 2. a score of or above 22 in moca; 3. a score of or above 60 in the chinese version of edinburgh handedness inventory; 4. no first-degree family members having a diagnosis of mental illnesses. 5. the age ≥ 13 years. at-risk participants and healthy controls will be excluded if they have any neurological / musculoskeletal dysfunction that may affect their upper-limb movements. for schizophrenia patients: the inclusion criteria for schizophrenia patients are: 1. a diagnosis of schizophrenia without other psychiatric diseases; 2. having stable psychotic symptoms; 3. a score of or above 22 in hk-moca; 4. a score of or above 60 in the chinese version of edinburgh handedness inventory. 5. the age ≥ 18 years. the inclusion criteria for healthy controls are: 1. a score below the cut-off score of cpq-16, cape-c15, and spq-b; 2. a score of or above 22 in moca; 3. a score of or above 60 in the chinese version of edinburgh handedness inventory; 4. no first-degree family members having a diagnosis of mental illnesses. 5. the age ≥ 18 years. patients and healthy controls will be excluded if they have any neurological / musculoskeletal dysfunction that may affect their upper-limb movements.
influence of topical indomethacin on hypothensive effect of brimonidine

Conditions: Glaucoma

Summary: purpose: to evaluate the influence of the nonsteroidal anti-inflammatory indomethacin on the brimonidine intraocular pressure (iop) lowering effect. methods: a randomized double-masked study was carried out. patients medicated with timolol maleate 0,5% and needed complementary medication were random allocated into two groups: (a) brimonidine tartarate 0,15% and indomethacin 1% or (b) brimonidine tartarate and placebo (balanced saline solution). if patient's both eyes were eligible, they were allocated to the same group. iop was measured at two weeks, one month and two months after study beginning. the mean iop of the eyes was used for analyzes, in the case of two eligible eyes. for statistical analyzes repeated measures analysis was used.


Eligibility criteria:
inclusion criteria: * primary open-angle glaucoma or ocular hypertension patients with the following criteria: 18 years of age or older, insufficient response to monotherapy with timolol maleate 0,5%, and adequate compliance in follow-up treatment exclusion criteria: * hypersensitivity to eyedrop solutions, insufficient compliance in follow-up treatment, pregnancy or childbearing potential.
the sublimated mare milk supplement in hepatitis c

Conditions: Hepatitis C

Summary: this clinical trial studies the effect of sublimated mare milk supplement on patients with hepatitis c.

chronic viral hepatitis c is one of the medical, social and economic public health problems throughout the world. in majority of patients with chronic viral hepatitis c, dysbiotic changes are detected in the intestinal tract. disturbances of microbial equilibrium are associated with the degree of inflammation, morphological changes in the liver, nature of the course and the stage of the disease. these dysbiotic changes and and associated immune disorders can significantly aggravate the course of immune processes in the liver, converting hepatitis c infection to a chronic disease. mare milk is frequently reported for having therapeutic and dietary properties, which are initially associated with a specific chemical composition and certain physical properties of the product. it contains a total of about 40 biologically active components, the most important of them vitamins a, c, b1, b2, b6, b12, amino acids, enzymes and trace elements, there are low molecular weight peptides, lactalbumins and globulins. the use of mare milk can contribute to the restoration of impaired functions of damaged organs and tissues, and play the role of an auxiliary pathogenetic therapy, primarily in certain chronic diseases of the digestive system, including chronic viral hepatitis c. mare milk can also be used as a powder supplement through sublimation process. in this trial, the effect of this supplement consisting of sublimated mare milk on hepatitis c patients will be evaluated. there will be two parallel groups: interventional (sublimated mare milk supplement with standard treatment) and standard treatment group. differences in laboratory characteristics will be quantitively analyzed between groups.

Eligibility criteria:
inclusion criteria: * patients with verified diagnosis of hepatitis c * aged 18 to 65 years * normal intestinal microbiota composition (anaerobes-95%, aerobes-5%) * normal level of immune system markers in blood (immunoglobulin m and immunoglobulin g) * decreased levels of phosphatidylethanolamine, phosphatidylserine, phosphatidylcholine, sphingomyelin * elevated lysophosphatidylcholine * willingness to consent to participate in the study * consent to adhere to treatment exclusion criteria: * drug and/or alcohol dependence * allergy to dairy products * people with mental disabilities and/or life-threatening conditions * pregnancy and/or lactation * lactose intolerance * refusal to participate in the study

Keywords: hepatitis c mare milk liver function
implementation of quality of life diagnostics and therapy

Conditions: Breast Neoplasms

Summary: implementation and evaluation of implementation of quality of life diagnostics and therapy in individual patients with breast cancer. a prospective study including 170 patients, 5 clinics and 38 general practitioners as coordinating doctors for quality of life therapies. correlational study including several comparisons such as patients and their doctors.

improving cancer patients' quality of life (ql) requires that ql-diagnostics, the availability of ql-enhancing treatment options and treatment decisions are being integrated into a clinical path. this description presents the development and implementation of such a clinical path in the tumorcenter regensburg. the acting persons and institutions in this clinical path are the breast cancer patients, the hospitals, the family doctors or gynaecologists, and a ql-study team. starting point is the ql-assessment either in the hospital or in doctors' practice (eortc qlq-c30 plus br-23). the caring physician documents the patients' health status. based on these two pieces of information, the ql-study team writes up a medical/ql-opinion plus therapy recommendation. this report is sent to the caring physician. the effectiveness of the therapy recommendation is assessed in the following ql-assessment. this clinical path is implemented via three interrelated methods of implementation: local opinion leaders, outreach visits, and quality circle. a total of 38 physicians were made familiar with ql-diagnostics through outreach visits, and 12 opinion leaders were identified and convinced to support this project. the quality circle provided regular cme meetings on ql-enhancing therapy options (pain control, psychotherapy, physiotherapy, nutrition, social rehabilitation). a total of 170 ql-reports were sent to physicians. all 38 doctors found the ql-profiles comprehensible and the therapy recommendations clinically relevant. the most common ql-problems were emotional functioning, fatigue, and arm/shoulder problems. ql-diagnostics is a new way to individualise and to rationalise patient care. it transforms the ql-concept into a decision-relevant, integral part of a clinical path that aims to provide high quality patient care.

Eligibility criteria:
inclusion criteria: * all patients with primary breast cancer in the county of regensburg, amberg and sulzbach-rosenberg in the year 2003 to june 2004 submitted by coordinating physicians who were trained in quality of life questionnaires and profiles. exclusion criteria: * secondary breast cancer, patients who refused to participate, patients incapable of filling out questionnaires, male patients, pregnant patients, age below 18 yrs.

Keywords: quality of life breast cancer referee's report diagnostics therapy
a study comparing ex vivo mri versus radiography of breast specimens

Conditions: Breast Cancer

Summary: radiography of breast specimens is currently the only radiological procedure used to verify removal of microcalcifications and presence of tumor-free margins after breast surgical resection. ex vivo mri will be tested for its ability to detect residual tumor tissue not detected by radiography in resected breast tumor specimens and/or its ability to verify tumor-free margins in breast cancer detected by mri only.


Eligibility criteria:
inclusion criteria: * women with malignant breast disease identified by microcalcifications without clinically evident disease * women candidate to breast preserving surgery exclusion criteria: * cardiac pacemaker, defibrillators, cardiac monitors * brain stimulators, implantable spinal stimulators * vascular and aneurismal clips * hemostatic clips * infusion pumps * glaucoma drainage implants * metallic foreign body positioned in vital organ of the patients * some heart valves * some vascular access ports, infusion pumps and catheters * permanent contraceptive tubal device * kidney disease

Keywords: breast cancer mri mammography microcalcifications local staging of breast microcalcifications evaluation of ex vivo mri for breast malignancies detected by mri only
propolis for patients with chronic kidney disease.

Conditions: Chronic Kidney Diseases; Inflammation

Summary: to evaluate the effects of propolis extract on inflammation in participants with chronic kidney disease. specific objectives to assess before and after the intervention period: * the expression of transcription factors (nuclear factor-kb), antioxidant enzymes (heme-oxygenase-1), inflammasome receptor, peroxisome proliferator-activated receptor-γ, as well as the levels of inflammatory cytokines (il-6, tumor nuclear factor-α, c-reactive protein, interleukin 1) and e-selectin adhesion molecules; * the levels of protein expression of inflammatory markers and antioxidant enzymes; * the profile of the intestinal microbiota of stool samples from the research participants; * plasma levels of substances reactive to thiobarbituric acid and oxidized low density lipoprotein as a marker of oxidative stress; * routine and anthropometric laboratory variables, indicative of the metabolic profile of the research participants; * assess blood pressure, 6-minute walk test, recovery heart rate and chair lift test to assess the functional capacity of the research participants; * assess atherogenic risk; * food intake and nutritional status; compare data between the intervention and control groups.

chronic kidney disease (ckd) has chronic systemic inflammation as an important component of multifactorial origin, a factor related to both the progression and outcomes of ckd, being involved in all causes of mortality in these patients, such as cardiovascular disease. in this context, some nutritional strategies have been proposed as an adjuvant therapeutic alternative to modulate inflammation, starting from the consolidated knowledge of the role of nutrients and bioactive compounds on the expression of genes related to inflammation and oxidative stress, factors that feed on each other. in view of this scenario, propolis, a substance made up of a combination of several chemical components with broad potential biological activity, appears as a promising alternative to modulate inflammation in patients with ckd. however, clinical evidence to assess the effects of propolis in patients with ckd is scarce, and there are no studies that have investigated its effects on gene expression and markers related to inflammation in these patients. thus, the present project proposes a longitudinal study of the clinical trial type that aims to evaluate the effects of propolis alcoholic extract on transcription factors and inflammatory markers in patients with ckd.

Eligibility criteria:
inclusion criteria: • aged 18 years or older - with fistula arteriovenous exclusion criteria: * patients pregnant * smokers * using antibiotics in the last three months * using antioxidant supplements as antioxidant vitamins, probiotic, prebiotic, symbiotic and antibiotics in the last three months * clinical diagnosis of infectious diseases * clinical diagnosis of cancer * clinical diagnosis of aids - for pd patients - no peritonitis

Keywords: chronic kidney disease non-dialysis propolis inflammation
screening for diabetic macular edema among diabetic patients using optical coherence tomography

Conditions: Diabetic Macular Edema

Summary: diabetic macular edema is one of the major causes of visual impairment in diabetic retinopathy patients especially in the working age group. the problem is likely to increase in the future with statistics showing a growing number of the diabetic population especially in the middle east . .

the worldwide prevalence of diabetic macular edema was reported as 6.81% among patients with diabetes. other research reported that the 10-year incidence of diabetic macular edema was 14% in individuals with type 2 diabetes, and progression to diabetic macular edema occurred in 29% of individuals with type 1 diabetes over 25 years if left untreated . although diabetic macular edema resolves spontaneously in about 33% to 35% of patients, it tends to be chronic in most patients..diabetic macular edema can occur at any stage of diabetic retinopathy . the symptoms of diabetic macular range from slight visual blurring to complete blindness if left untreated . optical coherence tomography is an objective non-invasive method for high-resolution cross-sectional imaging of the retina .

Eligibility criteria:
inclusion criteria: * patients with type 1or type 2 diabetes mellitus. * fundus examination and optical coherence tomography can be done with no significant hazy media exclusion criteria: 1. previous ocular surgery (e.g. vitreo-retinal surgery, glaucoma surgery). 2. presence of co-existing retinal or choroidal disease (e.g. high myopia, retinitis pigmentosa and age-related macular degeneration) 3. other associated ocular conditions (ex. glaucoma \& corneal opacity \& iritis). 4. previous history of trauma. 5. pregnancy induced diabetes
mobilization of endothelial progenitor cells and aspirin

Conditions: Hypertrophic Obstructive Cardiomyopathy

Summary: aspirin at doses used during acute myocardial infarction may inhibit the mobilization of endothelial progenitor cells (epcs).

aspirin has been shown to lower the number of epcs in a time- and concentration-dependent manner. in vitro studies also show that aspirin may reduce the migratory and adhesive capacity of isolated epcs, inhibit inos and tubule formation, which are pre-requisites for angiogenesis. this is relevant when patients are given a loading dose of 325mg at the time of diagnosis of acute myocardial infarction where higher numbers of epcs have been associated with better outcomes. furthermore, in the plato (platelet inhibition and patient outcomes) trial, high dose aspirin appeared to counteract the beneficial effect seen when ticagrelor or clopidogrel was used with low doses of aspirin in acute coronary syndromes (acs). as aspirin is currently standard of care in the management of acs, it is difficult to conduct a study of the effect of aspirin versus placebo in that scenario. however, during alcohol septal ablation for hypertrophic obstructive cardiomyopathy, the indication for an antiplatelet agent is not well defined and varies between operators. when a small amount of myocardium is deliberately destroyed in this process, it serves as an ideal model to study the effect of aspirin on the biology of epcs in vivo. this could provide an explanation to the different effects of high versus low dose aspirin when combined with a second antiplatelet agent in the management of acs.

Eligibility criteria:
inclusion criteria: 1. patients who have been selected to undergo alcohol septal ablation for hypertrophic obstructive cardiomyopathy based on clinical need 2. age \>18 years, \<80 years exclusion criteria: 1. patients with known allergy to aspirin 2. inability or refusal to consent to participate in the study 3. patients who are on non-steroidal anti-inflammatory drugs and cannot be stopped for the duration of the study

Keywords: endothelial progenitor cells aspirin acetylsalicylic acid alcohol septal ablation
personalized cardiovascular risk information to initiate and maintain health behavior changes

Conditions: Cardiovascular Disease; Peripheral Artery Disease; Ischemic Stroke; Diabetes

Summary: the investigators propose an evaluation that will assess three important components of risk communication: 1. provide patients with personalized risk communication using the risk calculator developed by fimdm and health information taken from the living with coronary artery disease program 2. provide personalized tailored patient feedback to help initiate and maintain specific cardiovascular cvd-related behaviors(e.g., medication adherence, exercise, diet, smoking cessation) to reduce their risks. 3. evaluate how this feedback can be incorporated into clinical care by examining 3 month patient outcome and provider responses to the risk information.

patients at high risk for cvd events frequently underestimate their risk. programs to improve cvd outcomes have largely focused on single risk factors and do not contextualize the information with a patient's global risk. an easy, accessible strategy to address global cvd risk based on personalized risk communication feedback with assistance with initiating and maintaining health behaviors has several advantages, but has not formally been tested. a patient's perceived risk of stroke or heart attack is an important factor in understanding motivation for risk reducing behaviors. lower perceived risk has been associated with poorer adherence to recommended health behaviors. additionally, a person's beliefs about his or her risk for a disease increased the likelihood of a more informed and activated patient, and figures prominently in models of health behavior (e.g., health belief model). people tend to underestimate their own risk; therefore providing accurate risk communication has the potential to activate patients to initiate and maintain behavior changes.

Eligibility criteria:
inclusion criteria: * cardiovascular disease (cvd) * cvd risk equivalent (peripheral arterial disease, history of ischemic stroke, or diabetes) exclusion criteria: * metastatic cancer, * dementia, * active psychosis * end-stage renal disease * no access to computer with internet

Keywords: cardiovascular disease